Chinese instructions for Copanlisib

1. Indications:

Copanliside/Copanisib is a PI3kinase inhibitor used to treat certain types of leukemia and lymphoma, specifically adult follicular lymphoma (Follicular Lymphoma), a subtype of non-Hodgkin lymphoma.

2. Mechanism of action:

Copanliside/Copanisib affects the proliferation, survival and angiogenesis of cancer cells by inhibiting the activity of the phosphatidylinositol3 kinase (PI3K) pathway. This pathway is extremely active in a variety of cancers, and the mechanism of action of copanliside/copanisib helps curb the growth of cancer cells.

3. Pharmacology:

Copanliside/Copanisib is rapidly distributed in the body, highly selective, and mainly acts on PI3Kδ and PI3Kα isoforms. It enters cancer cells and inhibits cell growth through inhibition of the PI3K pathway. In addition, Copanliside/Copanisib also has the effect of inhibiting tumor angiogenesis, thus inhibiting the blood supply to cancer tumors.

4. Dosage and usage:

1.Copanliside/CopanisibUsually administered by intravenous injection.

2.Recommended first doseCopanliside/CopanisibInject 60mg once a week for 3 weeks.

3.Then, the maintenance dose is 60mg every two weeks.

4.The patient's blood cell count and liver function need to be closely checked before use.

5. Side effects:

1.Common side effects include low white blood cell count, high blood sugar, high blood pressure, diarrhea, nausea, vomiting, fatigue, etc.

2.Severe adverse reactions may include infection, abnormal liver function, skin diseases, etc.

3.Copanliside/Kupanisi may cause allergic reactions, such as rash, itching, shortness of breath, etc.

6. Warnings and precautions:

1.The use ofcopanliside/copanisib requires close monitoring of the patient's blood cell count, especially the white blood cell count.

2.Blood sugar levels should be monitored regularly during drug use because copanliside/copanisib can cause hyperglycemia.

3.Adjustment of the treatment plan or interruption of treatment may be necessary to manage serious adverse reactions.

4.Pregnant women should avoid using copanliside/copanisib because it may cause harm to the fetus.

7. Contraindications:

Patients who are allergic tocopanliside/copanisib or other drug ingredients.

Pregnant and lactating women.

8. Drug interactions:

Copanliside/Copanisib may interact with other drugs, so before starting treatment you should tell your doctor about all the drugs you are taking, including prescription drugs, over-the-counter drugs, and supplements.

It may be necessary to adjust the dosage of other medications or choose alternative treatments.

9. Medication for special groups:

1.For adult patients, usually not for children.

2.In elderly patients, dose adjustment may be necessary.

3.Dose adjustment may be necessary in patients with impaired renal function.

4.Pregnant and lactating women should avoid using copanliside/copanisib.

10. Listing and price situation:

Copanliside/Kupanisi has just been launched in China and has not been included in medical insurance. The specific price may not be determined yet. Please consult your local pharmacy for details. There is only the American version of the original drug available abroad, and the price is as high as more than 70,000 yuan.

Copanliside/Copanisib is a targeted drug used to treat follicular lymphoma. It interferes with the proliferation and survival of cancer cells by inhibiting the activity of the PI3K pathway. During use, patients should be closely monitored for blood parameters and adverse reactions to ensure safe and effective treatment. Patients should discuss their specific conditions, including drug interactions and medication precautions for special populations, with their doctor before using copanliside/copanisib.